Your browser doesn't support javascript.
loading
Corrigendum to "Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study" [Clin Therapeut 42 (12) (2020) 2254-2265].
Smith, Timothy R; Janelidze, Marina; Chakhava, George; Cady, Roger; Hirman, Joe; Allan, Brent; Pederson, Susan; Smith, Jeff; Schaeffler, Barbara.
Afiliación
  • Smith TR; StudyMetrix Research, St. Peters, MO, USA. Electronic address: tsmith@studymetrix.com.
  • Janelidze M; Department of Neurology, Tbilisi State Medical University, Tbilisi, Georgia.
  • Chakhava G; Multiprofile Clinic Consilium Medulla, Georgian Association of Medical Specialties, Tbilisi, Georgia.
  • Cady R; Lundbeck Seattle BioPharmaceuticals Inc, Bothell, WA, USA.
  • Hirman J; Pacific Northwest Statistical Consulting Inc, Woodinville, WA, USA.
  • Allan B; Alder BioPharmaceuticals Inc (now Known as Lundbeck Seattle BioPharmaceuticals Inc), Bothell, WA, USA.
  • Pederson S; Lundbeck Seattle BioPharmaceuticals Inc, Bothell, WA, USA.
  • Smith J; Alder BioPharmaceuticals Inc (now Known as Lundbeck Seattle BioPharmaceuticals Inc), Bothell, WA, USA.
  • Schaeffler B; Lundbeck Seattle BioPharmaceuticals Inc, Bothell, WA, USA.
Clin Ther ; 43(4): 791, 2021 Apr.
Article en En | MEDLINE | ID: mdl-33814199
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Clin Ther Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Clin Ther Año: 2021 Tipo del documento: Article